J&J’s Janssen and BIDMC team up on Covid-19 vaccine SHARE

16 MARCH 2020

Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has partnered with the Beth Israel Deaconess Medical Center (BIDMC) to advance Covid-19 vaccine development.

The partners started pre-clinical testing of different vaccine prospects. The aim is to select a vaccine candidate for clinical trials by the end of this month.

Janssen expects to launch a Phase I clinical trial by the end of the year. The company is also working to upscale production and manufacturing capacities to meet public vaccination needs globally.

J&J chief scientific officer Paul Stoffels said: “It is critical to work with the best scientific minds as we look to rapidly identify and develop solutions to the Covid-19 outbreak. We are grateful for talented and experienced collaboration partners like Dan Barouch and his team at BIDMC.


Print Friendly, PDF & Email

Chris J. Stewart

Chris currently serves as Chief Executive Officer of Surgio Health as well as Chief Operating Officer at Ortho Spine Partners. Prior to that, he was the assistant vice president and business unit leader of Medical Device Management for HealthTrust Purchasing Group (HPG).

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button